The global next generation sequencing (NGS) market is expected to register a robust CAGR of around 15% over the next five years. This growth is primarily driven by the rising adoption of precision ...

Key opportunities in the precision oncology market include the rising adoption of personalized therapies, growth in ...

Illumina (ILMN) has returned to profitability, reporting high quality earnings and trading at $123.54 per share, which is below its estimated fair value of $166.88. The company is forecasting EPS ...

Founded by former Illumina, Grail and Google leaders, Hepta is applying the technological, genomic and commercialization expertise that made liquid biopsy possible in oncology to the far larger field ...

Illumina’s third quarter results reflected stable year-over-year revenue and a notable beat on Wall Street’s profit ...

. Illumina, Inc. (NASDAQ:ILMN) is one of the last week's best-performing stocks. Illumina rallied by 23.4 percent ...

According to Mordor Intelligence, the global companion diagnostics market is valued at USD 8.70 billion in 2025 and is projected to surpass USD 15.62 billion by 2030, growing at a CAGR of 12.42% ...

According to Mordor Intelligence, the global companion diagnostics market is valued at USD 8.70 billion in 2025 and is projected to surpass ...

The ban, which has been in place since March 4 following President Trump's doubling of tariffs on China, is expected to be ...

China is set to ease restrictions on some Illumina products, giving the sequencing giant a partial reprieve. | China is set to ease restrictions on some Illumina products, giving the sequencing giant ...

Illumina Inc. said the Chinese government has lifted a ban on the company selling its DNA sequencing machines inside the country.

Illumina’s revenue was flat for the third quarter as the sequencing giant continues to deal with headwinds from a China sales ...